RT Journal Article
SR Electronic
T1 COVID-19 is associated with relative ADAMTS13 deficiency and VWF multimer formation resembling TTP
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20177824
DO 10.1101/2020.08.23.20177824
A1 Doevelaar, Adrian
A1 Bachmann, Martin
A1 Hölzer, Bodo
A1 Seibert, Felix S.
A1 Rohn, Benjamin S.
A1 Bauer, Frederic
A1 Witzke, Oliver
A1 Dittmer, Ulf
A1 Bachmann, Michael
A1 Yilmaz, Serap
A1 Dittmer, Rita
A1 Schneppenheim, Sonja
A1 Babel, Nina
A1 Budde, Ulrich
A1 Westhoff, Timm H.
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177824.abstract
AB Background Thrombotic microangiopathy (TMA) has been repeatedly described in COVID-19 and may contribute to SARS-CoV-2 associated hypercoagulability. The underlying mechanisms remain elusive. We hypothesized that endothelial damage may lead to substantially increased concentrations of Von Willebrand Factor (VWF) with subsequent relative deficiency of ADAMTS13.Methods A prospective controlled trial was performed on 75 patients with COVID-19 of mild to critical severity and 10 healthy controls. VWF antigen (VWF:Ag), ADAMTS13 and VWF multimer formation were analyzed in a German hemostaseologic laboratory.Results VWF:Ag was 4.8 times higher in COVID-19 patients compared to healthy controls (p< 0.0001), whereas ADAMTS13 activities were not significantly different (p = 0.24). The ADAMTS13/VWF:Ag ratio was significantly lower in COVID-19 than in the control group (24.4±20.5 vs. 79.7±33.2, p< 0.0001). Fourteen patients (18.7%) undercut a critical ratio of 10 as described in thrombotic thrombocytopenic purpura (TTP). Gel analysis of multimers resembled the TTP constellation with loss of the largest multimers in 75% and a smeary triplet pattern in 39% of the patients. The ADAMTS13/VWF:Ag ratio decreased continuously from mild to critical disease (ANOVA p = 0.026). Moreover, it differed significantly between surviving patients and those who died from COVID-19 (p = 0.001) yielding an AUC of 0.232 in ROC curve analysis.Conclusion COVID-19 is associated with a substantial increase in VWF levels, which can exceed the ADAMTS13 processing capacity resulting in the formation of large VWF multimers identical to TTP. The ADAMTS13/VWF:Ag ratio is an independent predictor of severity of disease and mortality. These findings render further support to perform studies on the use of plasma exchange in COVID-19 and to include VWF and ADAMTS13 in the diagnostic workup.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialMulti thematic study process ongoingFunding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committees of Ruhr-University Bochum (20-6886), University Hospital Essen (20-9214-BO) and the Medical Association Hamburg.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external datasets or supplementary material at other repositories.(Covid-19)Coronavirus disease 2019(SARS-CoV-2)SARS Coronavirus 2(VWF)Von Willebrand factor